Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Cited by (1,010)

Items 401–500 of 1,010

1. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis
   Fausto Petrelli, Raffaele Ardito, Karen Borgonovo, Veronica Lonati, Mary Cabiddu, Mara Ghilardi, Sandro Barni · 2018 · European Journal of Cancer
2. The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer
   Hao Chen, Wei Chong, Changcai Teng, Yueliang Yao, Xin Wang, Xue Li · 2019 · Cancer Science
3. Radioimmunotherapy for the treatment of head and neck cancer
   Sana D. Karam, David Raben · 2019 · The Lancet Oncology
4. Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
   Jong Yeob Kim, Keum Hwa Lee, Jeonghyun Kang, Édith Borcoman, Esma Saâda-Bouzid, Andreas Kronbichler, Sung Hwi Hong, Leandro F. M. Rezende, Shuji Ogino, NaNa Keum et al. · 2019 · Cancers
5. Molecular imaging biomarkers for immune checkpoint inhibitor therapy
   Pim P. van de Donk, Laura Kist de Ruijter, Marjolijn N. Lub–de Hooge, Adrienne H. Brouwers, Anthonie J. van der Wekken, Sjoukje F. Oosting, Rudolf S.N. Fehrmann, Derk Jan A. de Groot, Elisabeth G.E. de Vries · 2020 · Theranostics
6. Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline
   Emrullah Yilmaz, Nofisat Ismaila, Julie E. Bauman, Raetasha Sheavette Dabney, Gregory N. Gan, Richard C. Jordan, Marnie Kaufman, Kedar Kirtane, Sean Matthew McBride, Matthew Owen Old et al. · 2022 · Journal of Clinical Oncology
7. Combining radiotherapy with immunotherapy: the past, the present and the future
   Evert Jan Van Limbergen, Dirk De Ruysscher, Veronica Olivo Pimentel, Damiënne Marcus, Maaike Berbée, Ann Hoeben, Nicolle H. Rekers, Jan Theys, Ala Yaromina, Ludwig Jerome Dubois et al. · 2017 · British Journal of Radiology
8. Cancer-associated fibroblasts promote the survival of irradiated nasopharyngeal carcinoma cells via the NF-κB pathway
   Weiqiang Huang, Longshan Zhang, Mi Yean Yang, Xixi Wu, Xiaoqing Wang, Wenqi Huang, Yuan Lu, Hua Pan, Yin Wang, Zi‐Ci Wang et al. · 2021 · Journal of Experimental & Clinical Cancer Research
9. YKT6 , as a potential predictor of prognosis and immunotherapy response for oral squamous cell carcinoma, is related to cell invasion, metastasis, and CD8+ T cell infiltration
   Zongcheng Yang, Guangxing Yan, Lixin Zheng, Wenchao Gu, Fen Liu, Wei Chen, Xiujie Cui, Yue Wang, Ya‐Ling Yang, Xiyan Chen et al. · 2021 · OncoImmunology
10. EBV-associated diseases: Current therapeutics and emerging technologies
    Srishti Chakravorty, Behdad Afzali, Majid Kazemian · 2022 · Frontiers in Immunology
11. Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study
    Lawson Eng, Rinku Sutradhar, Yue Niu, Ning Liu, Ying Liu, Yosuf Kaliwal, Melanie Powis, Geoffrey Liu, Jeffrey M. Peppercorn, Philippe Lucien Bedard et al. · 2023 · Journal of Clinical Oncology
12. Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma
    Jeroen F. Vermeulen, Wim Van Hecke, Elisabeth J. M. Adriaansen, Mieke K. Jansen, Rianne G. Bouma, José Villacorta Hidalgo, Paul Fisch, Roel Broekhuizen, Wim G.M. Spliet, Marcel Kool et al. · 2017 · OncoImmunology
13. CD8+ T-cell exhaustion in cancer: mechanisms and new area for cancer immunotherapy
    Qifeng He, Yong Xu, Jun Li, Zheng‐Ming Huang, Xiuhui Li, Xiaochen Wang · 2018 · Briefings in Functional Genomics
14. Epigenetic modifiers as new immunomodulatory therapies in solid tumours
    Sandrine Aspeslagh, Daphné Morel, Jean‐Charles Soria, Sophie C. Postel-Vinay · 2018 · Annals of Oncology
15. Palliative Radiation Therapy for Head and Neck Cancers
    Amardeep S. Grewal, Joshua Jones, Alexander Lin · 2019 · International Journal of Radiation Oncology*Biology*Physics
16. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer
    Stephanie M Dorta-Estremera, Venkatesh L. Hegde, Ravaen Slay, Rachel Sun, Ananta V. Yanamandra, Courtney Nicholas, Sita M.K. Nookala, Gloria Sierra, Michael A. Curran, K. Jagannadha Sastry · 2019 · Journal for ImmunoTherapy of Cancer
17. Management of pulmonary toxicity associated with immune checkpoint inhibitors
    Myriam Delaunay, Grégoire Prévôt, Samia Collot, Laurent Guilleminault, Alain P. Didier, Julien Mazières · 2019 · European Respiratory Review
18. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
    Victor C. Kok · 2020 · Frontiers in Oncology
19. Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial
    Vijay Patil, Vanita Noronha, Sachin Babanrao Dhumal, Amit Joshi, Nandini N. Menon, Atanu Bhattacharjee, Suyash Sureshchandra Kulkarni, Suman Kumar Ankathi, Abhishek Mahajan, Nilesh Pandurang Sable et al. · 2020 · The Lancet Global Health
20. Immunotherapy in endometrial cancer: rationale, practice and perspectives
    Wenyu Cao, Xinyue Ma, Jean Victoria Fischer, Chenggong Sun, Beihua Kong, Qing Hua Zhang · 2021 · Biomarker Research
21. The Key Differences between Human Papillomavirus-Positive and -Negative Head and Neck Cancers: Biological and Clinical Implications
    S. Powell, L. Vu, W. Spanos, Dohun Pyeon · 2021 · Cancers
22. Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials
    Bo Zhang, Qiong Wu, You Lang Zhou, Xinyu Guo, Jun Ge, Jiaji Fu · 2018 · International Immunopharmacology
23. Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis
    Congzhou Mike Sha, Eric J. Lehrer, Clara Hwang, Daniel Michael Trifiletti, Heath B. Mackley, Joseph J. Drabick, Nicholas George Zaorsky · 2020 · Radiotherapy and Oncology
24. Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy
    Tay, Rebecca Y, Blackley, Elizabeth, McLean, Catriona, Moore, Maggie, Bergin, Peter, Gill, Sanjeev, Haydon, Andrew · 2017 · British Journal of Cancer
25. Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients
    Hyun-Bae Jie, Raghvendra Mohan Srivastava, Athanassios E. Argiris, Julie E. Bauman, Larry Kane, Robert Louis Ferris · 2017 · Cancer Immunology Research
26. Head and Neck Carcinoma Immunotherapy: Facts and Hopes
    Theresa L. Whiteside · 2017 · Clinical Cancer Research
27. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma
    Anjelica Hodgson, Elzbieta A. Slodkowska, Achim A. Jungbluth, Stanley K. Liu, Danny Vesprini, Danny Enepekides, Kevin McLughlin Higgins, Nora Katabi, Bin Xu, Michelle R. Downes · 2018 · The American Journal of Surgical Pathology
28. Targeting DNA repair in cancer: current state and novel approaches
    Apostolos Klinakis, Dimitris Karagiannis, Theodoros N Rampias · 2019 · Cellular and Molecular Life Sciences
29. Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm
    Caroline Robert, Aurélien Marabelle, Hugo Herrscher, Caroline Caramella, Pascal Rouby, Karim S. Fizazi, Benjamin Besse · 2020 · Nature Reviews Clinical Oncology
30. Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?
    Mojtaba Mollaei, Zuhair Mohammad Hassan, Fatemeh Khorshidi, Ladan Langroudi · 2021 · Translational Oncology
31. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine
    Valentin Van den Bossche, Hannah Zaryouh, Marianela Vara-Messler, Julie Vignau, Jean‐Pascal Machiels, An Wouters, Sandra Schmitz, Cyril Corbet · 2022 · Drug Resistance Updates
32. Hyperprogression as a distinct outcome after immunotherapy
    Jesús Fuentes‐Antrás, Mariano Provencio, Eduardo Díaz‐Rubio · 2018 · Cancer Treatment Reviews
33. Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)
    Yungan Tao, Anne Auperin, Xu-Shan Sun, Christian Sire, Laurent Martin, Alexandre Coutté, Cédrik Lafond, Jessica Miroir, X. Liem, Frédéric Rolland et al. · 2020 · European Journal of Cancer
34. Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
    Andrea Botticelli, Alessio Cirillo, Lidia Strigari, Filippo Valentini, Bruna Cerbelli, Simone Scagnoli, Edoardo Cerbelli, Ilaria Grazia Zizzari, Carlo Della Rocca, Giulia d’Amati et al. · 2021 · Frontiers in Immunology
35. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
    Robert I. Haddad, Tanguy Y. Seiwert, Laura Q.M. Chow, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Ann Burtness, Makoto Tahara, Bhumsuk Keam et al. · 2022 · Journal for ImmunoTherapy of Cancer
36. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
    Brendan D. Curti, Yoshinobu Koguchi, Rom S. Leidner, Annah S. Rolig, Elizabeth R. Sturgill, Zhaoyu Sun, Yaping Wu, Venkatesh Rajamanickam, Brady M. Bernard, Ian Hilgart-Martiszus et al. · 2021 · Journal for ImmunoTherapy of Cancer
37. Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment
    Hridesh Banerjee, Hector M Nieves-Rosado, Aditi Kulkarni, Benjamin Murter, Kyle V. McGrath, Uma R. Chandran, Alexander Chang, Andrea L. Szymczak-Workman, Lazar N. Vujanovic, Greg M. Delgoffe et al. · 2021 · Cell Reports
38. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors
    Tosi, Anna, Parisatto, Beatrice, Menegaldo, Anna, Spinato, Giacomo, Guido, Maria, Del Mistro, Annarosa, Bussani, Rossana, Zanconati, Fabrizio, Tofanelli, Margherita, Tirelli, Giancarlo et al. · 2022 · Journal of Experimental & Clinical Cancer Research
39. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
    Panagiotis Balermpas, Franz Rödel, Mechthild Krause, Annett Linge, Fabian Lohaus, Michael A. Baumann, Ingeborg Tinhofer, Volker Budach, Ali Sak, Martin Stuschke et al. · 2017 · International Journal of Cancer
40. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
    Vanessa Bernstein, Susan L. Ellard, Susan Faye Dent, Dongsheng Tu, Mihaela Mates, Sukhbinder Dhesy‐Thind, Lawrence Panasci, Karen A. Gelmon, Mohammad Salim, X. Song et al. · 2017 · Breast Cancer Research and Treatment
41. Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence
    Biagio Ricciuti, Giulia Costanza Leonardi, Paolo Puccetti, Francesca Fallarino, Vanessa Bianconi, Amirhossein Sahebkar, Sara Baglivo, Rita Chiari, Matteo Pirro · 2018 · Pharmacology & Therapeutics
42. Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial
    Robert I. Haddad, Fernando Concha‐Benavente, George R. Blumenschein, Jérôme Fayette, Joël Guigay, Alexander Dimitrios Colevas, Lisa Francesca Licitra, Stefan Kasper, Everett E. Vokes, Francis Paul Worden et al. · 2019 · Cancer
43. Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
    Christine H. Chung, Jiannong Li, Conor E. Steuer, Priyanka Bhateja, Matthew Johnson, Jude Masannat, Maria I. Poole, Feifei Song, Juan C. Hernandez-Prera, Helen Molina et al. · 2022 · Clinical Cancer Research
44. Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives
    Sameen Zafar, Amna Hafeez, Hania Shah, Iqra Mutiullah, Arslan Ali, Khushbukhat Khan, Gabriela Figueroa‐González, Octavio Daniel Reyes‐Hernández, Laura Itzel Quintas Granados, Sheila I. Peña‐Corona et al. · 2025 · European journal of medical research
45. High-resolution microbiome profiling uncoversFusobacterium nucleatum,Lactobacillus gasseri/johnsonii, andLactobacillus vaginalisassociated to oral and oropharyngeal cancer in saliva from HPV positive and HPV negative patients treated with surgery and chemo-radiation
    Rafael E. Guerrero-Preston, James Robert White, Filipa Godoy‐Vitorino, Arnold Rodríguez-Hilario, Kelvin Navarro, Herminio González, Christina Michailidi, Anne Jedlicka, Sierra Canapp, Jessica Bondy et al. · 2017 · Oncotarget
46. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs
    Austin K. Mattox, Jina Lee, William H. Westra, Robert Hamilton Pierce, Ronald A. Ghossein, William C. Faquin, Thomas J. Diefenbach, Luc G.T. Morris, Derrick T. Lin, Lori J. Wirth et al. · 2017 · Cancer Research
47. Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy
    Robert J. Torphy, Richard David Schulick, Yuwen Zhu · 2017 · International Journal of Molecular Sciences
48. Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
    Alberto Carretero-González, David Lora, Ismael Ghanem, Jon Zugazagoitia, Daniel Castellano, Juan Manuel Sepúlveda-Sánchez, Jose Antonio Lopez-Martin, Luis G Paz-Ares, Guillermo de Velasco · 2018 · Oncotarget
49. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer
    Maura L. Gillison, George R. Blumenschein, Jérôme Fayette, Joël Guigay, Alexander Dimitrios Colevas, Lisa Francesca Licitra, Kevin Joseph Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even et al. · 2018 · The Oncologist
50. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer
    Kenneth L. Kehl, Shihao Yang, Mark Magdi Awad, Nathan Palmer, Isaac S. Kohane, Deborah Schrag · 2019 · Cancer Immunology Immunotherapy
51. ISA101 and nivolumab for HPV-16 + cancer: updated clinical efficacy and immune correlates of response
    Luana Guimarães de Sousa, Kimal Rajapakshe, Jaime Rodriguez Canales, Renee L. Chin, Lei Feng, Qi Wang, Tomás Zecchini Barrese, Erminia Massarelli, William William, Faye M. Johnson et al. · 2022 · Journal for ImmunoTherapy of Cancer
52. Potential roles of Cornichon Family AMPA Receptor Auxiliary Protein 4 (CNIH4) in head and neck squamous cell carcinoma
    Hengrui Liu, Yixue Li, Yue Han · 2022 · Cancer Biomarkers
53. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)
    Makoto Tahara, Naomi Kiyota, T. Yokota, Y. Hasegawa, Kei Muro, S. Takahashi, T. Onoe, Akihiro Homma, Jun Taguchi, Masami Suzuki et al. · 2018 · Annals of Oncology
54. Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy
    Maxime Frélaut, Pauline du Rusquec, Alexandre De Moura, Christophe Le Tourneau, Édith Borcoman · 2020 · BioDrugs
55. Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress
    Wuchang Zhang, Wei Liu, Lingfei Jia, Demeng Chen, Insoon Chang, Michael P. Lake, Laurent A. Bentolila, Cun‐Yu Wang · 2021 · Molecular Cell
56. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy
    Soomin Ahn, Kyoung‐Mee Kim · 2021 · Modern Pathology
57. Targeting TIGIT for cancer immunotherapy: recent advances and future directions
    Peng Zhang, Xinyuan Liu, Zhuoyu Gu, Zhongxing Jiang, Song Q Zhao, Yongping Song, Jifeng Yu · 2024 · Biomarker Research
58. Salvage surgery in recurrent head and neck squamous cell carcinoma: Oncologic outcome and predictors of disease free survival
    Marc Hamoir, Emma Holvoet, Jérôme Ambroise, Benoît Lengelé, Sandra Schmitz · 2017 · Oral Oncology
59. TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma
    Julien Adam, Emilie Louvet, Tony Sourisseau, Nicolas Dorvault, Marine Bernard, Elodie Maingot, Laura Faivre, Mei-Shiue Kuo, Émilie Boissier, Marie-Charlotte Dessoliers et al. · 2018 · ESMO Open
60. A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure
    Amer Methqal Zeidan, Hanna A. Knaus, Tara M. Robinson, Andrea M. H. Towlerton, Edus Houston Warren, Joshua F. Zeidner, Amanda L. Blackford, Amy S. Duffield, David Alan Rizzieri, Mark G. Frattini et al. · 2018 · Clinical Cancer Research
61. Immune Checkpoint Inhibitors in Oral Cavity Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Systematic Review
    Omar Kujan, Bede van Schaijik, Camile Selim Farah · 2020 · Cancers
62. Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects
    Tianhang Li, Tianyao Liu, Wenjie Zhu, Shangxun Xie, Zihan Zhao, Baofu Feng, Hongqian Guo, Rong Yang · 2021 · Clinical Medicine Insights Oncology
63. Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy
    Hirofumi Shibata, Shin Saito, Ravindra Uppaluri · 2021 · Frontiers in Oncology
64. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma
    Hannah M. Knochelmann, Joshua Dean Horton, Sixue Liu, Kent E. Armeson, John M. Kaczmar, Megan M. Wyatt, Mary S. Richardson, Shirley H. Lomeli, Ying Xiong, Evan Michael Graboyes et al. · 2021 · Cell Reports Medicine
65. Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols
    Catherine T. Haring, Lulia A. Kana, Sarah M. Dermody, Collin V. Brummel, Jonathan Brad McHugh, Keith A. Casper, Steven Bennett Chinn, Kelly Michele Malloy, Michelle Lynn Mierzwa, Mark E. Prince et al. · 2023 · Cancer
66. Aging, immune senescence, and immunotherapy: a comprehensive review
    Elias, Rawad, Hartshorn, Kevan, Rahma, Osama, Lin, Nina, Snyder-Cappione, Jennifer E. · 2018 · Seminars in Oncology
67. PD ‐1 and PD ‐L1 expression in HNSCC primary cancer and related lymph node metastasis – impact on clinical outcome
    Sven Schneider, Lorenz Kadletz, Robert Wiebringhaus, Lukas Kenner, Edgar Selzer, Thorsten Füreder, Orsolya Rajky, Anna Sophie Berghoff, Matthias Preusser, Gregor Heiduschka · 2018 · Histopathology
68. 10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma
    Lei Chen, Yuan Zhang, Shu-Zhen Lai, Wen‐Fei Li, Wei‐Han Hu, Rui Sun, Lizhi Liu, Fan Zhang, Hao Peng, Xiao-Jing Du et al. · 2018 · The Oncologist
69. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer
    Yoshie Kobayashi, Seung‐Oe Lim, Hirohito Yamaguchi · 2019 · Seminars in Cancer Biology
70. Update on oral and oropharyngeal cancer staging – International perspectives
    Masanari G. Kato, C. Baek, P. Chaturvedi, R. Gallagher, L. P. Kowalski, C. Leemans, S. Warnakulasuriya, Shaun A. Nguyen, T. Day · 2020 · World Journal of Otorhinolaryngology-Head and Neck Surgery
71. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting
    Sonia Aristín Revilla, Onno Kranenburg, Paul James Coffer · 2022 · Frontiers in Immunology
72. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer
    Alemohammad, Hajar, Najafzadeh, Basira, Asadzadeh, Zahra, Baghbanzadeh, Amir, Ghorbaninezhad, Farid, Najafzadeh, Arezoo, Safarpour, Hossein, Bernardini, Renato, Brunetti, Oronzo, Sonnessa, Margherita et al. · 2022 · Biomedicine & Pharmacotherapy
73. Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report
    Sarah E. Paraghamian, Teresa C. Longoria, Ramez Nassef Eskander · 2017 · Gynecologic Oncology Research and Practice
74. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade
    Jean‐Philippe Foy, Chloé Bertolus, Marie‐Cécile Michallet, Sophie Deneuve, Roberto Incitti, Nathalie Bendriss‐Vermare, Marie Alexandra Albaret, Sandra Ortiz‐Cuaran, Emilie Thomas, Amélie Colombe et al. · 2017 · Annals of Oncology
75. PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy
    Verena Rolfes, Christian Idel, Ralph Pries, Kirstin Plötze‐Martin, Jens Karsten Habermann, Timo Gemoll, Sabine Bohnet, Eicke Latz, Julika Ribbat‐Idel, Bernardo S. Franklin et al. · 2018 · Oncotarget
76. A Comparison of Grade 4 Lymphopenia With Proton Versus Photon Radiation Therapy for Esophageal Cancer
    David M. Routman, Aurélie Garant, Scott C. Lester, Courtney N. Day, William Scott Harmsen, Cristobal T. Sanheuza, Harry H. Yoon, Michelle A. Neben-Wittich, James A. Martenson, Michael G. Haddock et al. · 2019 · Advances in Radiation Oncology
77. Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma
    Karamboulas, Christina, Bruce, Jeffrey P., Hope, Andrew J., Meens, Jalna, Huang, Shao Hui, Erdmann, Natalie, Hyatt, Elzbieta, Pereira, Keira, Goldstein, David P., Weinreb, Ilan et al. · 2018 · Cell Reports
78. Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy
    Ilio Vitale, Antonella Sistigu, Gwenola Manic, Nils-Petter Rudqvist, Zlatko Trajanoski, Lorenzo Galluzzi · 2019 · Trends in Cell Biology
79. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
    Tokiyoshi Tanegashima, Yosuke Togashi, Koichi Azuma, Akihiko Kawahara, Ko Ideguchi, Daisuke Sugiyama, Fumio Kinoshita, Jun Akiba, Eiji Kashiwagi, Ario Takeuchi et al. · 2019 · Clinical Cancer Research
80. A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses
    Wenjie Zhai, Xiuman Zhou, Hongfei Wang, Wanqiong Li, Guanyu Chen, Xinghua Sui, Guodong Li, Yuanming Qi, Yanfeng Gao · 2020 · Acta Pharmaceutica Sinica B
81. The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: A gene expression-based study
    Lizao Zhang, Bowen Li, Peng Yu, Fan Wu, Qunxing Li, Zhaoyu Lin, Shule Xie, Liping Xiao, Xinyu Lin, Zhanpeng Ou et al. · 2020 · Oral Oncology
82. Epidemiological Trends of Head and Neck Cancer: A Population‐Based Study
    Kangwen Guo, Weiliang Xiao, Xinggui Chen, Zhenying Zhao, Yuanxiong Lin, Ge Chen · 2021 · BioMed Research International
83. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors
    Kimberley M. Heinhuis, Matteo Salvatore Carlino, Markus Joerger, Massimo Di Nicola, Tarek M. Meniawy, Sylvie Rottey, Víctor Moreno, Anas Gazzah, Jean‐Pierre Delord, Luis G Paz-Ares et al. · 2019 · JAMA Oncology
84. Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab
    Mioko Matsuo, Ryuji Yasumatsu, Muneyuki Masuda, Satoshi Toh, Takahiro Wakasaki, Kazuki Hashimoto, Masahiko Taura, Ryutaro Uchi, Takashi Nakagawa · 2019 · Oral Oncology
85. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non–Small Cell Lung Cancer
    Baptiste Kas, Hugues Talbot, Roberto Ferrara, Colombe Richard, Jean-Philippe Lamarque, Stéphanie Pitre-Champagnat, David Planchard, Corinne Balleyguier, Benjamin Besse, Laura Mezquita et al. · 2020 · JAMA Oncology
86. Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies
    Franco Ionna, Paolo Bossi, Agostino Guida, Andrea Alberti, Paolo Muto, Giovanni Salzano, Alessandro Ottaiano, Fabio Maglitto, Davide Leopardo, Marco De Felice et al. · 2021 · Cancers
87. Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck
    Bhumsuk Keam, Jean-Pascal Machiels, Hye Ryun Kim, Lisa Francesca Licitra, Wojciech Golusiński, Vincent Grégoire, Y.G. Lee, Claus Belka, Ye Guo, Senthil Jagannathan Rajappa et al. · 2021 · ESMO Open
88. Targeting tumour-intrinsic N 7 -methylguanosine tRNA modification inhibits MDSC recruitment and improves anti-PD-1 efficacy
    Hai‐Ning Liu, Xuezhen Zeng, Xuxin Ren, Yifan Zhang, Manling Huang, Li Tan, Zihao Dai, Jiaming Lai, Wenxuan Xie, Zebin Chen et al. · 2022 · Gut
89. Macrophage-Mediated Subversion of Anti-Tumour Immunity
    Valeria Quaranta, Michael C. Schmid · 2019 · Cells
90. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
    Byoung Chul Cho, Amaury Daste, Alain Ravaud, Sébastien Salas, Nicolás Isambert, Edward Francis McClay, Ahmad Hussein Awada, Christian Borel, Laureen S. Ojalvo, Christoph Helwig et al. · 2020 · Journal for ImmunoTherapy of Cancer
91. Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
    Anthony Richard Cillo, Elina Mukherjee, Nathanael G. Bailey, Sayali Onkar, Jessica D. Daley, Cláudia Maria Salgado, Xiang Li, Dongyan Liu, Sarangarajan Ranganathan, Melissa Amber Burgess et al. · 2022 · Clinical Cancer Research
92. Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma
    Chan-Young Ock, Sehui Kim, Bhumsuk Keam, Soyeon Kim, Yong‐Oon Ahn, Eun‐Jae Chung, Jin-Ho Kim, Tae Min Kim, Seong Keun Kwon, Yoon Kyung Jeon et al. · 2017 · Oncotarget
93. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
    Ignacio Garcia Matos, Juan Martín-Liberal, Alonso García-Ruiz, Cinta Hierro, María Ochoa de Olza, Cristina Viaplana, Analía Azaro, María Vieito, Irene Braña, Gemma Mur et al. · 2019 · Clinical Cancer Research
94. Hyperprogressive Disease in Patients with Non–Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of 18 F-FDG PET/CT
    Angelo Castello, Sabrina Rossi, Emanuela Mazziotti, Luca Toschi, Egesta Lopci · 2019 · Journal of Nuclear Medicine
95. Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses
    Joel Kidman, Nicola Principe, Mark W Watson, Timo Lassmann, Robert A. Holt, Anna K. Nowak, Willem Joost Lesterhuis, Richard Lake, Jonathan Chee · 2020 · Frontiers in Immunology
96. Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments
    Mahmoud S. Alghamri, Brandon L. McClellan, Carson S. Hartlage, Santiago Haase, Syed Mohd Faisal, Rohit Thalla, Ali A. Dabaja, Kaushik Banerjee, Stephen V. Carney, Anzar Mujeeb et al. · 2021 · Frontiers in Pharmacology
97. Current Treatment Strategies and Risk Stratification for Oral Carcinoma
    Issa Mohamad, Mica D. E. Glaun, Kumar Prabhash, Ahmed Busheri, Stephen Yenzen Lai, Vanita Noronha, Ali Hosni · 2023 · American Society of Clinical Oncology Educational Book
98. Glioblastoma vaccines: past, present, and opportunities
    Zujian Xiong, Itay Raphael, Michael R. Olin, Hideho Okada, Xuejun Li, Gary Kohanbash · 2024 · EBioMedicine
99. Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells
    Friedman, Jay, Moore, Ellen C., Zolkind, Paul, Robbins, Yvette, Clavijo, Paul E., Sun, Lilian, Greene, Sarah, Morisada, Megan V., Mydlarz, Wojciech K., Schmitt, Nicole et al. · 2020 · Clinical Cancer Research
100. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
     Terry A. Day, Keisuke Shirai, Paul E. O’Brien, Maria Gisele Matheus, Kristina Godwin, Amit J. Sood, Anvesh Reddy Kompelli, Julie A. Vick, Daniel Martı́n, Lynn A. Vitale-Cross et al. · 2018 · Clinical Cancer Research